CO2022008272A2 - Agentes de unión a ilt3 y métodos de uso de los mismos - Google Patents

Agentes de unión a ilt3 y métodos de uso de los mismos

Info

Publication number
CO2022008272A2
CO2022008272A2 CONC2022/0008272A CO2022008272A CO2022008272A2 CO 2022008272 A2 CO2022008272 A2 CO 2022008272A2 CO 2022008272 A CO2022008272 A CO 2022008272A CO 2022008272 A2 CO2022008272 A2 CO 2022008272A2
Authority
CO
Colombia
Prior art keywords
binding agents
methods
same
ilt3
ilt3 binding
Prior art date
Application number
CONC2022/0008272A
Other languages
English (en)
Inventor
Yan Wang
Suzanne Christine Crawley
Jer-Yuan Hsu
Daniel David Kaplan
Betty Chan Li
Vicky Yi-Bing Lin
Seth Malmersjö
Kevin James Paavola
Julie Michelle Roda
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CO2022008272A2 publication Critical patent/CO2022008272A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a ILT3, incluido ILT3 humano, así como composiciones que comprenden los agentes de unión y métodos para su uso. La divulgación también proporciona polinucleótidos relacionados y vectores que codifican los agentes de unión y células que comprenden los agentes de unión.
CONC2022/0008272A 2019-12-19 2022-06-13 Agentes de unión a ilt3 y métodos de uso de los mismos CO2022008272A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950434P 2019-12-19 2019-12-19
PCT/US2020/065642 WO2021127200A1 (en) 2019-12-19 2020-12-17 Ilt3-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2022008272A2 true CO2022008272A2 (es) 2022-08-30

Family

ID=74554203

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0008272A CO2022008272A2 (es) 2019-12-19 2022-06-13 Agentes de unión a ilt3 y métodos de uso de los mismos

Country Status (16)

Country Link
US (2) US11760802B2 (es)
EP (1) EP4077394A1 (es)
JP (1) JP2023507110A (es)
KR (1) KR20220130671A (es)
CN (2) CN114901691A (es)
AR (1) AR120822A1 (es)
AU (1) AU2020405036A1 (es)
BR (1) BR112022011790A2 (es)
CA (1) CA3164642A1 (es)
CL (1) CL2022001622A1 (es)
CO (1) CO2022008272A2 (es)
IL (1) IL293869A (es)
MX (1) MX2022007288A (es)
PE (1) PE20221263A1 (es)
TW (1) TW202136304A (es)
WO (1) WO2021127200A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009434A1 (en) * 2021-07-28 2023-02-02 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
US20230220076A1 (en) * 2021-12-21 2023-07-13 Ngm Biopharmaceuticals, Inc. Combinational use of an anti-ilt3 antibody and an anti-lair-1 antibody
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
TW202346337A (zh) 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
WO2023209716A1 (en) 2022-04-25 2023-11-02 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0644877B2 (ja) 1986-12-26 1994-06-15 寳酒造株式会社 抗ヒト・フイブロネクチンモノクロ−ナル抗体
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
WO2003000199A2 (en) 2001-06-25 2003-01-03 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2006036813A2 (en) 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2992017B1 (en) 2013-05-02 2020-11-18 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
EP3256163A4 (en) 2015-02-11 2018-10-10 University Health Network Methods and compositions for modulating lilr proteins
CA3218106A1 (en) 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
JP2018025554A (ja) 2016-07-29 2018-02-15 国立大学法人東北大学 炎症性疾患のマーカー
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. ILT3 LIGAND
WO2018148494A1 (en) 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
US20200147099A1 (en) 2017-06-20 2020-05-14 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
GEP20237565B (en) 2017-11-17 2023-11-10 Merck Sharp & Dohme Llc Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
US20210122819A1 (en) 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
MX2022001756A (es) 2019-08-13 2022-05-18 Tohoku Techno Arch Co Ltd Inhibidor del punto de control inmunitario, agente terapeutico para la enfermedad relacionada con el punto de control inmunitario, inmunosupresor, anticuerpo contra la fibronectina o derivado del mismo, analogo de la fibronectina, kit para detectar la fibronectina o una proteina parcial de la misma, y metodo para detectar la fibronectina o una proteina parcial de la misma.

Also Published As

Publication number Publication date
MX2022007288A (es) 2022-07-12
AR120822A1 (es) 2022-03-23
US20240043533A1 (en) 2024-02-08
US11760802B2 (en) 2023-09-19
JP2023507110A (ja) 2023-02-21
KR20220130671A (ko) 2022-09-27
AU2020405036A1 (en) 2022-07-07
CL2022001622A1 (es) 2023-03-24
EP4077394A1 (en) 2022-10-26
CN114901691A (zh) 2022-08-12
IL293869A (en) 2022-08-01
PE20221263A1 (es) 2022-08-16
WO2021127200A8 (en) 2022-07-14
WO2021127200A1 (en) 2021-06-24
US20210221887A1 (en) 2021-07-22
CN115746138A (zh) 2023-03-07
BR112022011790A2 (pt) 2022-08-30
CA3164642A1 (en) 2021-06-24
TW202136304A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
CO2022018537A2 (es) Agentes de unión a lair-1 y métodos para su uso
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2017003021A1 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
EA201890390A1 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CL2021001506A1 (es) Anticuerpos que se unen a cd3
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
EA201890337A1 (ru) Конструкции антитела к flt3 и cd3
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
UY38391A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anti hla-g
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
CL2020002522A1 (es) Agentes de unión a c3 y métodos para su uso
CL2021003343A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3.
UY33274A (es) Proteínas de unión a basigina
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
CL2020002680A1 (es) Anticuerpos para radionúclidos quelados
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
AR122678A1 (es) Agentes de unión a lair-1 y métodos para su uso